| 1 | 16833545 | Remarkable reactivities of the xanthone ketyl radical in the excited state compared with that in the ground state. | J Phys Chem A | 2005 Mar 24 |
1 |
| 2 | 27573426 | AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. | Mol Cancer Ther | 2016 Nov |
12 |
| 3 | 28073847 | Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors. | Clin Cancer Res | 2017 Feb 15 |
6 |
| 4 | 28378926 | Translational Modeling of Drug-Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor. | CPT Pharmacometrics Syst Pharmacol | 2017 Jun |
2 |
| 5 | 29596834 | AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo. | Biochem Biophys Res Commun | 2018 May 15 |
17 |
| 6 | 29636547 | BRD4 facilitates replication stress-induced DNA damage response. | Oncogene | 2018 Jul |
2 |
| 7 | 29931583 | Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. | Invest New Drugs | 2019 Apr |
16 |
| 8 | 30036377 | BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. | PLoS One | 2018 |
4 |
| 9 | 30304769 | A Novel t(8;14)(q24;q11) Rearranged Human Cell Line as a Model for Mechanistic and Drug Discovery Studies of NOTCH1-Independent Human T-Cell Leukemia. | Cells | 2018 Oct 9 |
2 |
| 10 | 30308485 | AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo. | Cell Physiol Biochem | 2018 |
10 |
| 11 | 30696721 | Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study. | Oncologist | 2019 Aug |
1 |
| 12 | 31142662 | The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. | Mol Cancer Ther | 2019 Aug |
10 |
| 13 | 31199520 | Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer. | Int J Cancer | 2020 Feb 15 |
1 |
| 14 | 31523195 | BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor. | Int J Biol Sci | 2019 |
11 |
| 15 | 32184777 | BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages. | Front Immunol | 2020 |
6 |
| 16 | 33407870 | Two-step generation of mesenchymal stem/stromal cells from human pluripotent stem cells with reinforced efficacy upon osteoarthritis rabbits by HA hydrogel. | Cell Biosci | 2021 Jan 6 |
8 |
| 17 | 33574760 | Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials. | Front Pharmacol | 2020 |
1 |
| 18 | 33717143 | Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function. | Front Immunol | 2021 |
2 |
| 19 | 33838899 | Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification. | J Pediatr Surg | 2021 Jul |
6 |
| 20 | 34160250 | SARS-CoV-2 Spike Protein Induces Paracrine Senescence and Leukocyte Adhesion in Endothelial Cells. | J Virol | 2021 Aug 10 |
5 |
| 21 | 34693628 | Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor. | Pediatr Blood Cancer | 2022 Feb |
2 |
| 22 | 34942306 | AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway. | Cancer Lett | 2022 Mar 1 |
5 |
| 23 | 35399501 | AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells. | Front Cell Dev Biol | 2022 |
9 |
| 24 | 35480096 | MUS81 Inhibition Enhances the Anticancer Efficacy of Talazoparib by Impairing ATR/CHK1 Signaling Pathway in Gastric Cancer. | Front Oncol | 2022 |
3 |